Novel peg-modified enzyme and anticancer agent delivery using same

The purpose of the invention is to provide a novel anticancer agent delivery technique. More specifically, the purpose of the invention is to provide a novel anticancer agent delivery technique in which an enzyme that decomposes components in cancer tissue or in the interstitium therearound is caused to migrate effectively to the cancer tissue, thereby lowering the interstitial pressure of the cancer tissue and making it possible to disperse an anticancer agent in the cancer tissue efficiently. The purpose of the invention is also to provide a novel PEGylated enzyme that can be used in the technique. The invention provides a complex comprising an enzyme, cyclodextrin, and polyethylene glycol, the complex being characterized in that the enzyme is bromelain or hyaluronidase to which at least one adamantane is covalently bonded; in the complex, the cyclodextrin and polyethylene glycol are covalently bonded, and the cyclodextrin and adamantane are bonded by a host-guest interaction.